May 10, 2008

| CHI Conferences > Global R&D Congress: Discovery and Development Operations in Emerging Regions

Conference Menu

Overview
Day 1
Day 2
Register
PDF Download
Welcome Letter
Hotel & Travel
Sponsor
Press Pass
Request Brochure
Complimentary Webcast

Corporate Sponsors:

Supporting Association:

Lead Sponsoring Publications:

Sponsoring Publications:

Web Partners:

Global R&D Congress: Discovery and Development Operations in Emerging Regions

Register Yourself and a Peer (within or outside of your organization) at the Same Time
to Receive our VIP Rate!
Call David Cunningham at +1 781-972-5472 or Email cunningham@healthtech.com

This program is equal to 1.5 CEU's

Click here to view a list of Global R&D Congress Alumni

FEATURED PRESENTATIONS
	A Critical Evaluation of Preclinical Testing in China: A Case Study Dr. Diana Galer, Vice President, Strategic Management Group, Pfizer, Inc.	Developing a Global Strategy to Further Innovation Ross Horsburgh, Regional Medical Director, Asia Pacific & Head CRR-APAC, AstraZeneca
	Assessing Which Regions are Most Attractive and Why: A Perspective Balu Balasubramanian, Ph.D., Executive Director, Research and Development, Bristol-Myers Squibb Co.	Data Acceptability and Requirements in China: A Risk/Benefit Analysis Dr. Lee Jia, Project Officer, Toxicology and Pharmacology Branch, DTP, National Cancer Institute/NIH
	Quality vs. Speed: A Regulatory Perspective on the Future Direction of Chinese SFDA and Role of China in Global Drug Development Zili Li, M.D., M.P.H., Director of Clinical Research Operations-Asia Pacific/Head of China Regulatory Policy, Merck	Translational Medicine and Biomarker Development Collaborations in China Jingsong Wang, Ph.D., Director, Clinical Discovery, Bristol-Myers Squibb
	Outsourcing Lead Generation Activities in China, India, and Russia Deborah S. Hartman, Ph.D., Vice President, Lead Generation, AstraZeneca	How to Best Manage R&D Operations in China to Maximize Productivity Samantha Ying Du, Ph.D., CEO, Hutchison MediPharma Ltd.
	R&D in Russia Today: Regulatory Overview and Best Practices when Working with Local Authorities Elena Barmanova, Deputy Director, Office for Registration of Drugs and Medical Devices, Federal department for Surveillance in Healthcare, Roszdravnadzor, Russia	Operational Challenges when Sourcing the Globe for Discovery Efforts Gilles Cottier, President, Sigma-Aldrich

Planning a Global Strategy Around Intellectual Property Law: IP Barriers, and Trends

Partnering for Medicinal Chemistry, Pharmacology, Animal Models, and GLP Tox
Beyond chemistry and biology outsourcing, what can be done outside of the US and Europe and what are the true possibilities, costs, constraints and efficiencies?

Intellectual Property • Partnering and Collaborations • Regulatory Landscape and Drug Registration • Deals, Licensing, and Risk-sharing • Accessing, Keeping and Managing Talent • International Project and Team Management • Discovery Chemistry • Discovery Biology • Pre-clinical Safety • Investigational Product Supply • Translational Medicine

Distinguished Faculty
•	Balu Balasubramanian, Ph.D., Executive Director, Research and Development, Bristol-Myers Squibb Co.	•	Col. Aizen J. Marrogi, M.D., Department of Pathology and Area Laboratory Service, Walter Reed Army Medical Center
•	Dr. Diana Galer, Vice President, Strategic Management Group, Pfizer, Inc.	•	Dr. David Moskowitz, CEO, GenoMed, Inc.
•	Deborah S. Hartman, Ph.D., Vice President, Lead Generation, AstraZeneca	•	Dr. Vyas Shingatgeri, Director, Drug Safety Evaluation, Ranbaxy Research Laboratories
•	Mak Jawadekar, Ph.D., Director, WWPM, Pﬁzer Global R&D	•	Vijay Soni, Executive Vice President – IP, Glenmark Pharma
•	Gregory E. Kalbaugh, Director and Counsel, U.S.-India Business Council	•	Mr. Omar Vikin, Director, Global Strategic Accounts, Sigma-Aldrich Corporation
•	Lee Jia, Ph.D., Project Manager, Toxicology and Pharmacology Branch, DTP, National Cancer Institute/NIH	•	Jingsong Wang, Ph.D., Director, Clinical Discovery, Bristol-Myers Squibb
•	Zili Li, M.D., M.P.H., Director of Clinical Research Operations-Asia Pacific/Head of China Regulatory Policy, Merck	•	Samantha Ying Du, Ph.D., CEO, Hutchison MediPharma Ltd.
•	Dr. Ying Luo, CEO, GNI, Ltd. and Shanghai Genomics, Inc.	•	Elena Barmanova, Deputy Director, Office for Registration of Drugs and Medical Devices, Federal department for Surveillance in Healthcare, Roszdravnadzor, Russian Federation
•	Dhanapalan Nagarathnam, Ph.D., Director, Medicinal Chemistry, Pharmasset, Inc.	•	Ross Horsburgh, Regional Medical Director, Asia Pacific & Head CRR-APAC, AstraZeneca
•	Gopala Krishna, PhD, DABT, MBA, Senior Director and Head, Preclinical Candidate Evaluation, Supernus Pharmaceuticals, Inc.	•	Kelly P. Longo, Director, Strategic Alliances, Pfizer Inc.
•	Cris Howard, MBA, MEd, Senior Manager, Clinical Operations, Emergent BioSolutions	•	Sudhir Borgonha, M.D., Chief Executive Officer, Translational Medicine India
•	Donald Swankie, Director, Neeman Medical International	•	Gilles Cottier, President, Sigma-Aldrich
•	Art Gertel, Vice President, Clinical Services, Regulatory, & Medical Writing Beardsworth Consulting Group, Inc.	•	Robert Ward, Vice President, Alliance Management, NPS Pharmaceuticals
•	M. (Ken) Kengatharan, Ph.D., MBA, Vice President, Scientific Affairs, CoMentis Inc.	•	Pavle Vukojevic, M.D., Global Medical Director, Pharm-Olam International Ltd.
•	Frank J. Malinoski, MD, Ph.D., Senior Vice President, Medical and Scientific Affairs, MedImmune, Inc.	•	Dr. Paul D’Sylva, CEO, Commonwealth Biotechnologies, Inc. (CBI)
•	Edward J. Brennan, Jr., MD, FACS, President and CEO, IndiPharm LLC

Featuring Two Presentations Focusing on Issues at the
Forefront of Drug Development in Asia

Wednesday, April 30 from 12:30 PM -1:30 PM ET (US)

View Full Details

Presentation 1-CHINA:
Conducting High Quality, Cost Effective GLP Safety Studies in China -- Moving from If and When to HOW

Presentation 2-INDIA:
CASE STUDY: How Moving a POC Study to India Took 12+ Months off the Timeline for a Western Biotech

By Series:
By Region: